Global Antibody Hit Generation and Screening Market: Analysis and Forecast, 2023-2032

Table of Contents

Executive Summary

Scope of the Study

Research Methodology

1. Market

• 1.1. Global Market Outlook
• 1.2. Product Definition
• 1.3. Inclusion and Exclusion Criteria
• 1.4. Key Findings
• 1.5. Assumptions and Limitations
• 1.6. Global Market Scenario
  • 1.6.1. Realistic Scenario
  • 1.6.2. Optimistic Scenario
  • 1.6.3. Pessimistic Scenario
• 1.7. Industry Outlook
• 1.8. Key Trends
• 1.9. Patent Analysis
  • 1.9.1. Awaited Technological Developments
  • 1.9.2. Patent Filing Trend (by Country/Cluster)
  • 1.9.3. Patent Filing Trend (by Year)
• 1.10. Product Benchmarking
• 1.11. Impact of COVID-19 on Global Antibody Hit Generation and Screening Market
• 1.12. Impact on Market Size
  • 1.12.1. Pre-COVID-19 Phase
  • 1.12.2. During-COVID-19 Phase
  • 1.12.3. Post-COVID-19 Phase
• 1.13. Market Entry Barriers and Opportunities
• 1.14. Business Dynamics
• 1.15. Impact Analysis
  • 1.15.1. Business Drivers
  • 1.15.2. Business Restraints
  • 1.15.3. Business Opportunities

2. Global Antibody Hit Generation and Screening Market (by Technologies)

• 2.1. Opportunity Assessment
• 2.2. Growth Share Matrix
  • 2.2.1. Hit Generation
  • 2.2.2. Phage display
  • 2.2.3. Yeast display
  • 2.2.4. Ribosome display
  • 2.2.5. B-cell hybridoma technology
  • 2.2.6. Computational tools
  • 2.2.7. Screening

3. Global Antibody Hit Generation and Screening Market (by Antibody Type)

• 3.1. Opportunity Assessment
• 3.2. Growth Share Matrix
  • 3.2.1. Humanized Antibody
  • 3.2.2. Human Antibody
  • 3.2.3. Chimeric Antibody
  • 3.2.4. Murine Antibody

4. Global Antibody Hit Generation and Screening Market (by Applications)

• 4.1. Opportunity Assessment
• 4.2. Growth Share Matrix
  • 4.2.1. Cancer
  • 4.2.2. Autoimmune diseases
  • 4.2.3. Infectious diseases

5. Region

• 5.1. North America Antibody Hit Generation and Screening Market
• 5.2. Key Findings and Opportunity Assessment
• 5.3. Regulatory Framework
• 5.4. Market Dynamics
  • 5.4.1. Impact Analysis
• 5.5. Sizing and Forecast Analysis
  • 5.5.1. North America Antibody Hit Generation and Screening Market (by Technologies)
  • 5.5.2. North America Antibody Hit Generation and Screening Market (by Country)
    • 5.5.2.1.1. U.S.
    • 5.5.2.1.2. Canada
• 5.6. Europe Antibody Hit Generation and Screening Market
• 5.7. Key Findings and Opportunity Assessment
• 5.8. Regulatory Framework
• 5.9. Market Dynamics
  • 5.9.1. Impact Analysis
• 5.10. Sizing and Forecast Analysis
  • 5.10.1. Europe Antibody Hit Generation and Screening Market (by Technologies)
  • 5.10.2. Europe Antibody Hit Generation and Screening Market (by Country)
    • 5.10.2.1.1. Germany
    • 5.10.2.1.2. France
    • 5.10.2.1.3. U.K.
    • 5.10.2.1.4. Italy
    • 5.10.2.1.5. Spain
    • 5.10.2.1.6. Rest-of-Europe
• 5.11. Asia-Pacific Antibody Hit Generation and Screening Market
• 5.12. Key Findings and Opportunity Assessment
• 5.13. Regulatory Framework
• 5.14. Market Dynamics
  • 5.14.1. Impact Analysis
• 5.15. Sizing and Forecast Analysis
  • 5.15.1. Asia-Pacific Antibody Hit Generation and Screening Market (by Technologies)
  • 5.15.2. Asia-Pacific Antibody Hit Generation and Screening Market (by Country)
    • 5.15.2.1.1. Japan
    • 5.15.2.1.2. China
    • 5.15.2.1.3. Australia
    • 5.15.2.1.4. India
    • 5.15.2.1.5. South Korea
    • 5.15.2.1.6. Rest-of-Asia-Pacific
• 5.16. Latin America Antibody Hit Generation and Screening Market
• 5.17. Key Findings and Opportunity Assessment
• 5.18. Regulatory Framework
• 5.19. Market Dynamics
  • 5.19.1. Impact Analysis
• 5.20. Sizing and Forecast Analysis
  • 5.20.1. Latin America Antibody Hit Generation and Screening Market (by Technologies)
  • 5.20.2. Latin America Antibody Hit Generation and Screening Market (by Country)
    • 5.20.2.1.1. Brazil
    • 5.20.2.1.2. Mexico
    • 5.20.2.1.3. Rest-of-Latin America
• 5.21. Rest-of-the-World Antibody Hit Generation and Screening Market
• 5.22. Key Findings and Opportunity Assessment
• 5.23. Regulatory Framework
• 5.24. Market Dynamics
  • 5.24.1. Impact Analysis
• 5.25. Sizing and Forecast Analysis
  • 5.25.1. Rest-of-the-World Antibody Hit Generation and Screening Market (by Technologies)

6. Markets

• 6.1. Competitive Benchmarking and Company Profiles
• 6.2. Competitive Landscape
  • 6.2.1. Key Strategies and Developments
    • 6.2.1.1.1. Partnerships, Alliances, and Business Expansion
    • 6.2.1.1.2. Funding Activities
    • 6.2.1.1.3. New Offerings
    • 6.2.1.1.4. Mergers and Acquisitions
    • 6.2.1.1.5. Regulatory and Legal Activities
• 6.3. Company Profiles
  • 6.3.1. F. Hoffmann-La Roche Ltd.
  • 6.3.2. Company Overview
  • 6.3.3. Product Portfolio
  • 6.3.4. Financials
  • 6.3.5. Recent Developments
  • 6.3.6. Analyst Perspective
  • 6.3.7. AbbVie
  • 6.3.8. Pfizer
  • 6.3.9. AstraZeneca
  • 6.3.10. Novartis
  • 6.3.11. Eli Lilly
  • 6.3.12. WuXi AppTec
  • 6.3.13. Charles River Laboratories
  • 6.3.14. Syngenta
  • 6.3.15. BioLegend
  • 6.3.16. Creative Biolabs
  • 6.3.17. Eurofins CDMO
  • 6.3.18. AbCellera
  • 6.3.19. MorphoSys
  • 6.3.20. Evelo Biosciences
  • 6.3.21. Icos Therapeutics
  • 6.3.22. Argenx
  • 6.3.23. Kymab
  • 6.3.24. Alnylam Pharmaceuticals
  • 6.3.25. SAb Biotherapeutics
  • 6.3.26. Other Companies

* Financials are provided for the public companies only